Menu Search
Equities

Rani Therapeutics Holdings Inc

RANI:NMQ

Rani Therapeutics Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.34
  • Today's Change0.03 / 1.30%
  • Shares traded106.15k
  • 1 Year change-15.52%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Rani Therapeutics Holdings Inc's net income fell 11.06% from a loss of 30.59m to a larger loss of 33.97m despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-95.14%
Return on equity-227.14%
Return on investment-154.95%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Rani Therapeutics Holdings Inc fell by 21.14m. However, Cash Flow from Investing totalled 29.86m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 51.24m for operations while cash generated from financing totalled 233.00k.
Cash flow per share-2.30
Price/Cash flow per share--
Book value per share0.056
Tangible book value per share0.056
More ▼

Balance sheet in USDView more

Rani Therapeutics Holdings Inc has a Debt to Total Capital ratio of 84.16%, a lower figure than the previous year's 121.46%.
Current ratio1.93
Quick ratio--
Total debt/total equity10.40
Total debt/total capital0.8416
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.